Skip to main content

Table 4 Test characteristics of multiple algorithms among patients aged ≥ 65 y

From: An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance

Algorithms [Pretest prevalence: 1.8%] TP TN FN FP Post-test prev.# Sensitivity [95 CI%] Specificity [95 CI%] PPV [95 CI%] NPV [95 CI%]
1 P AND ≥1 Rx ever 53 3248 10 115 4.9% 84 (75–93) 97 (96–97) 32 (25–39) 100 (100–100)
2 P AND ≥1 Rx ever 51 3318 12 45 2.8% 81 (71–91) 99 (98–99) 53 (43–63) 100 (99–100)
2 P ≥ 60 days apart AND ≥1 RX ever 49 3320 14 43 2.7% 78 (68–88) 99 (98–99) 53 (43–64) 100 (99–100)
(1 H ever) OR (2 P AND ≥1 Rx in 1 YR) 52 3337 11 26 2.3% 83 (73–92) 99 (99–100) 67 (56–77) 100 (100–100)
(1 H ever) OR (2 P AND ≥1 Rx in 2 YR) 52 3335 11 28 2.3% 83 (73–92) 99 (99–100) 65 (55–76) 100 (100–100)
(1 H ever) OR (2 P AND ≥1 RX in 3 YR) 52 3332 11 31 2.4% 83 (73–92) 99 (99–99) 63 (52–73) 100 (100–100)
(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥1 Rx in 1 YR) 52 3347 11 16 2.0% 83 (73–92) 100 (99–100) 77 (66–87) 100 (100–100)
(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥1 Rx in 2 YR) 52 3346 11 17 2.0% 83 (73–92) 100 (99–100) 75 (65–86) 100 (100–100)
(1 H ever) OR (2 P with ≥ 1 P by specialist AND ≥ 1 Rx in 3 YR) 52 3345 11 18 2.0% 83 (73–92) 100 (99–100) 74 (64–85) 100 (100–100)
(1 H ever) OR (3 P AND ≥ 1 Rx in 1 YR) 47 3346 16 17 1.9% 75 (64–85) 100 (99–100) 73 (63–84) 100 (99–100)
(1 H ever) OR (3 P AND ≥ 1 Rx in 2 YR) 48 3342 15 21 2.0% 76 (66–87) 99 (99–100) 70 (59–80) 100 (99–100)
(1 H ever) OR (3 P AND ≥ 1 Rx in 3 YR) 48 3342 15 21 2.0% 76 (66–87) 99 (99–100) 70 (59–80) 100 (99–100)
(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 1 YR) 47 3351 16 12 1.7% 75 (64–85) 100 (99–100) 80 (69–90) 100 (99–100)
(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 2 YR) 48 3349 15 14 1.8% 76 (66–87) 100 (99–100) 77 (67–88) 100 (99–100)
(1 H ever) OR (3 P with ≥ 1 P by specialist AND ≥ 1 Rx in 3 YR) 48 3348 15 15 1.8% 76 (66–87) 100 (99–100) 76 (66–87) 100 (99–100)
  1. Seniors 65+: N = 3426 patients (63 RA and 3363 non-RA); # = Post-test prevalence; TP = True Positive; TN = True Negative; FN = False Negative; FP = False Positive; H: Hospitalization code; P = physician diagnosis code; Specialist = rheumatologist, internal medicine, orthopedic surgeon; Rx refers to drug exposures: oral corticosteroid, disease-modifying anti-rheumatic drug (DMARD) or biologic; DMARDs included: Azathioprine, Chloroquine, Cyclophosphamide, Cyclosporine, Gold, Minocycline; and Biologics included: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab; Abatacept, Anakinra, Rituximab, Tocilizumab.